MPS II instrument, a unique, non invasive instrument for accurately and consistently measuring macular pigment in the retina. Low levels of macular pigment have been associated with the development of macular degeneration, a debilitating and leading cause of blindness. Early detection and management using a device like the MPS II can result in earlier therapeutic intervention and better patient outcomes. Screening programs conducted within optical practices and allied healthcare settings can effectively minimize the impact this condition has on a population, the consequent health management costs and resulting loss of impendence for sufferers. Attendees will develop an understanding of the product and the ways in which it can be used to successfully build a business with a recurring revenue stream.

Speaker: David Smith, Director, IDE - Ultrasound Technologies

David Smith has a 30+ year history in commercializing life science products. Early in his career he worked for large multinationals in the eye care and cardiovascular arenas, before starting his own vascular surgery business in 2004. This was subsequently sold to a NASDAQ listed business in 2014. Since then David has focused increasingly on interim CEO work and entrepreneurial ventures. IDE Vision was established in 2021 and purchased assets from Elektron Technology, a London Stock Exchange listed business to establish its foundational product range. David is a Fellow of The Chartered Institute of Marketing

Location: UK Presentation Theatre: Hall 16, J48